Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests
2
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Next-generation sequencing (NGS) has recently emerged as an essential component of personalized cancer medicine due to its high throughput and low per-base cost. However, no sufficient guidelines for implementing NGS as a clinical molecular pathology test are established in Korea. To ensure clinical grade quality without inhibiting adoption of NGS, a taskforce team assembled by the Korean Society of Pathologists developed laboratory guidelines for NGS cancer panel testing procedures and requirements for clinical implementation of NGS. This consensus standard proposal consists of two parts: laboratory guidelines and requirements for clinical NGS laboratories. The laboratory guidelines part addressed several important issues across multistep NGS cancer panel tests including choice of gene panel and platform, sample handling, nucleic acid management, sample identity tracking, library preparation, sequencing, analysis and reporting. Requirements for clinical NGS tests were summarized in terms of documentation, validation, quality management, and other required written policies. Together with appropriate pathologist training and international laboratory standards, these laboratory standards would help molecular pathology laboratories to successfully implement NGS cancer panel tests in clinic. In this way, the oncology community would be able to help patients to benefit more from personalized cancer medicine.
Abstract
Next-generation sequencing (NGS) has recently emerged as an essential component of personalized cancer medicine due to its high throughput and low per-base cost. However, no sufficient guidelines for implementing NGS as a clinical molecular pathology test are established in Korea. To ensure clinical grade quality without inhibiting adoption of NGS, a taskforce team assembled by the Korean Society of Pathologists developed laboratory guidelines for NGS cancer panel testing procedures and requirements for clinical implementation of NGS. This consensus standard proposal consists of two parts: laboratory guidelines and requirements for clinical NGS laboratories. The laboratory guidelines part addressed several important issues across multistep NGS cancer panel tests including choice of gene panel and platform, sample handling, nucleic acid management, sample identity tracking, library preparation, sequencing, analysis and reporting. Requirements for clinical NGS tests were summarized in terms of documentation, validation, quality management, and other required written policies. Together with appropriate pathologist training and international laboratory standards, these laboratory standards would help molecular pathology laboratories to successfully implement NGS cancer panel tests in clinic. In this way, the oncology community would be able to help patients to benefit more from personalized cancer medicine.
참고문헌 (47)
- Bentley DR, "Accurate whole human genome sequencing using reversible terminator chemistry", Nature, 456, pp.53~59 (2008)
- Metzker ML, "Sequencing technologies: the next generation", Nat Rev Genet, 11, pp.31~46 (2010)
- Aziz N, "College of American Pathologists' laboratory standards for next-generation sequencing clinical tests", Arch Pathol Lab Med, 139, pp.481~493 (2015)
- Rehm HL, "ACMG clinical laboratory standards for next-generation sequencing", Genet Med, 15, pp.733~747 (2013)
- Louis DN, "WHO classification of tumours of the central nervous system" (2016), IARC Press
- Burghel GJ, "Towards a next-generation sequencing diagnostic service for tumour genotyping: a comparison of panels and platforms", Biomed Res Int, 2015, pp.478017~ (2015)
- Hinrichs JW, "Comparison of next-generation sequencing and mutation-specific platforms in clinical practice", Am J Clin Pathol, 143, pp.573~578 (2015)
- McCourt CM, "Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis", PLoS One, 8, pp.e69604~ (2013)
- Hicks DG, "The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research", Biotech Histochem, 87, pp.14~17 (2012)
- Howat WJ, "Tissue fixation and the effect of molecular fixatives on downstream staining procedures", Methods, 70, pp.12~19 (2014)
- Do H, "Sequence artifacts in DNA from formalin-fixed tissues : causes and strategies for minimization", Clin Chem, 61, pp.64~71 (2015)
- Do H, "Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates", Clin Chem, 59, pp.1376~1383 (2013)
- Lin MT, "Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing", J Clin Pathol, 141, pp.856~866 (2014)
- Serizawa M, "The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues", Cancer Genet, 208, pp.415~427 (2015)
- Marchetti A, "Assessing EGFR mutations", N Engl J Med, 354, pp.526~528 (2006)
- 최성은, "Proposal of an Appropriate Decalcification Method of Bone Marrow Biopsy Specimens in the Era of Expanding Genetic Molecular Study", Journal of Pathology and Translational Medicine, 49(3), pp.236~242 (2015), 대한병리학회[DOI]
- Pengelly RJ, "A SNP profiling panel for sample tracking in whole-exome sequencing studies", Genome Med, 5, pp.89~ (2013)
- Brownstein CA, "An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge", Genome Biol, 15, pp.R53~ (2014)
- Cornish A, "A comparison of variant calling pipelines using genome in a bottle as a reference", Biomed Res Int, 2015, pp.456479~ (2015)
- Hwang S, "Systematic comparison of variant calling pipelines using gold standard personal exome variants", Sci Rep, 5, pp.17875~ (2015)
- Teo SM, "Statistical challenges associated with detecting copy number variations with next-generation sequencing", Bioinformatics, 28, pp.2711~2718 (2012)
- Onsongo G, "CNV-RF is a random forest-based copy number variation detection method using nextgeneration sequencing", J Mol Diagn, 18, pp.872~881 (2016)
- Frampton GM, "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing", Nat Biotechnol, 31, pp.1023~1031 (2013)
- Deans ZC, "Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL", Virchows Arch, 470, pp.5~20 (2017)
- "ISO 15189: 2012 Medical laboratories: requirements for quality and competence" (2012)[URL]
- "Nomenclature for the description of sequence variants" (2010)[URL]
- Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists", J Mol Diagn, 19, pp.4~23 (2017)
- "Use of standards in FDA regulatory oversight of next generation sequencing (NGS)-based in vitro diagnostics (IVDs) used for diagnosing germline diseases" (2016)[URL]
- Chin EL, "Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutations", BMC Genet, 14, pp.6~ (2013)
- Cottrell CE, "Validation of a nextgeneration sequencing assay for clinical molecular oncology", J Mol Diagn, 16, pp.89~105 (2014)
- Hagemann IS, "Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy", Cancer Genet, 206, pp.420~431 (2013)
- Williams ES, "Implementing genomic medicine in pathology", Adv Anat Pathol, 20, pp.238~244 (2013)
- Zook JM, "Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls", Nat Biotechnol, 32, pp.246~251 (2014)
- "GeT-RM Homo sapiens" (2017)[URL]
- Ajay SS, "Accurate and comprehensive sequencing of personal genomes", Genome Res, 21, pp.1498~1505 (2011)
- Gargis AS, "Assuring the quality of nextgeneration sequencing in clinical laboratory practice", Nat Biotechnol, 30, pp.1033~1036 (2012)
- Gargis AS, "Good laboratory practice for clinical next-generation sequencing informatics pipelines", Nat Biotechnol, 33, pp.689~693 (2015)
- "Clinical practice guidelines" (2009)[URL]
- "ESMO clinical practice guidelines" (2017)[URL]
- Cree IA, "Guidance for laboratories performing molecular pathology for cancer patients", J Clin Pathol, 67, pp.923~931 (2014)
- Luthra R, "Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges", Cancers, 7, pp.2023~2036 (2015)
- Schrijver I, "Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology", J Mol Diagn, 14, pp.525~540 (2012)
- "Clinical laboratory certification guidelines" (2016)[URL]
- Cheng DT, "Memorial Sloan KetteringIntegrated Mutation Profiling of Actionable Cancer Targets (MSKIMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology", J Mol Diagn, 17, pp.251~264 (2015)
- Fisher KE, "Clinical validation and implementation of a targeted next-generation sequencing assay to detect somatic variants in non-small cell lung, melanoma, and gastrointestinal malignancies", J Mol Diagn, 18, pp.299~315 (2016)
- Pritchard CC, "Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens", J Mol Diagn, 16, pp.56~67 (2014)
- Sikkema-Raddatz B, "Targeted nextgeneration sequencing can replace Sanger sequencing in clinical diagnostics", Hum Mutat, 34, pp.1035~1042 (2013)